<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02669940</url>
  </required_header>
  <id_info>
    <org_study_id>P15-743</org_study_id>
    <nct_id>NCT02669940</nct_id>
  </id_info>
  <brief_title>Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation - An Observational, Multi-Center Study</brief_title>
  <acronym>HCV RWE</acronym>
  <official_title>Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation - An Observational, Multi-Center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to assess the effectiveness, patient reported outcomes, work productivity
      and healthcare resource utilization of the interferon-free regimen of Paritaprevir
      (PTV)/ritonavir (r) - Ombitasvir (OBV), ± Dasabuvir (DSV), ± Ribavirin in chronic hepatitis C
      (CHC) participants in a real life setting across clinical practice populations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 15, 2016</start_date>
  <completion_date type="Actual">July 4, 2017</completion_date>
  <primary_completion_date type="Actual">July 4, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12)</measure>
    <time_frame>12 weeks after the last dose of study drug</time_frame>
    <description>Sustained virologic response is defined as hepatitis C virus ribonucleic acid (HCV RNA) levels less than the lower limit of quantification 12 weeks after the last dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Virological Response</measure>
    <time_frame>At 12 and 24 weeks after first dose of study drug</time_frame>
    <description>Virologic response is defined as HCV RNA less than 50 IU/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Relapse</measure>
    <time_frame>At 12 or 24 weeks after last dose of study drug</time_frame>
    <description>Relapse is defined as HCV RNA &lt;50 IU/mL at end of treatment followed by HCV RNA ≥50 IU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who achieved breakthrough</measure>
    <time_frame>From baseline until end of treatment: 12 or 24 weeks after first dose</time_frame>
    <description>Breakthrough is defined as at least one documented HCV RNA &lt;50 IU/mL followed by HCV RNA ≥50 IU/mL during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants meeting On-treatment Virologic Failure</measure>
    <time_frame>12 weeks after last dose of study drug</time_frame>
    <description>On-treatment virologic failure defined as breakthrough or failure to suppress each measured on-treatment HCV RNA value ≥50 IU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants meeting relapse</measure>
    <time_frame>12 weeks after last dose of study drug</time_frame>
    <description>Relapse defined as HCV RNA &lt;50 IU/mL at end of treatment or at the last on-treatment HCV RNA measurement followed by HCV RNA ≥50 IU/mL post-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants meeting premature study drug discontinuation with no on-treatment virologic failure</measure>
    <time_frame>12 weeks after last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants missing SVR12 data and/or none of the above criteria</measure>
    <time_frame>12 weeks after last dose of study drug</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">158</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Genotype 1</condition>
  <arm_group>
    <arm_group_label>Genotype 1 Chronic Hepatitis C</arm_group_label>
    <description>Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with the interferon-free ABBVIE REGIMEN ± Ribavirin (RBV) according to standard of care and in line with the current local label</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBVIE REGIMEN ± RBV</intervention_name>
    <description>tablet</description>
    <arm_group_label>Genotype 1 Chronic Hepatitis C</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Treatment-naïve or -experienced adult male or female patients with confirmed chronic
        hepatitis C genotype 1, receiving combination therapy with the interferon-free ABBVIE
        REGIMEN ± RBV according to standard of care and in line with the current local label
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients are eligible for observation in this cohort if the following applies:

          -  Treatment-naïve or -experienced adult male or female patients with confirmed CHC,
             genotype 1, receiving combination therapy with the interferon-free ABBVIE REGIMEN ±
             RBV according to standard of care and in line with the current local label

          -  If RBV is co-administered with the ABBVIE REGIMEN, it has been prescribed in line with
             the current local label (with special attention to contraception requirements and
             contraindication during pregnancy)

          -  Patients must voluntarily sign and date informed consent prior to inclusion into the
             study

          -  Patient must not be participating or intending to participate in a concurrent
             interventional therapeutic trial

        Exclusion Criteria:

          -  Patient must not be participating or intending to participate in a concurrent
             interventional therapeutic trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrey Strugovschikov, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GUZ Altai Territory Ctr for Disease Prevention of AIDS /ID# 148460</name>
      <address>
        <city>Barnaul</city>
        <zip>656010</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South-Ural State Med. Academy /ID# 148462</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454052</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution /ID# 148467</name>
      <address>
        <city>Irkutsk</city>
        <zip>664035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kazan State University /ID# 148459</name>
      <address>
        <city>Kazan</city>
        <zip>42012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Center for the Prevention and Control of AIDS /ID# 148461</name>
      <address>
        <city>Khabarovsk</city>
        <zip>680031</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KOGBUZ &quot;Kirovsk Infectious Clinical Hospital&quot; /ID# 151032</name>
      <address>
        <city>Kirov</city>
        <zip>610008</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Clinical Hospital #1 /ID# 148457</name>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital 24 /ID# 148458</name>
      <address>
        <city>Moscow</city>
        <zip>127015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Medical center Zdorovaya semya /ID# 148463</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Medical Company /ID# 148466</name>
      <address>
        <city>Samara</city>
        <zip>443063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Hospital n.a. S.P. Botkin /ID# 148470</name>
      <address>
        <city>St. Petersburg</city>
        <zip>191167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leningrad Regional Center for Prevention and Fight against A /ID# 148469</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPb SBIH &quot;Center for Prevention and Control of AIDS and Infe /ID# 151030</name>
      <address>
        <city>St.Petersburg</city>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavropol State Medical University /ID# 148456</name>
      <address>
        <city>Stavropol</city>
        <zip>355012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Clinica of Bashkir State Medical University /ID# 148465</name>
      <address>
        <city>Ufa</city>
        <zip>450015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Inst Ulyanovsk Regional Clinical Hospital /ID# 148468</name>
      <address>
        <city>Ulyanovsk</city>
        <zip>432057</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2016</study_first_submitted>
  <study_first_submitted_qc>January 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2016</study_first_posted>
  <last_update_submitted>July 21, 2017</last_update_submitted>
  <last_update_submitted_qc>July 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ombitasvir</keyword>
  <keyword>Dasabuvir</keyword>
  <keyword>Paritaprevir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

